Garcia-Muñoz, R. (., Quero, C. (., Pérez-Persona, E. (., Domingo-García, A. (., Pérez-López, C. (., Villaescusa-de-la-Rosa, T. (., . . . Panizo, C. (. (2020). Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: The Spanish population of the MabRella study.
Citación estilo ChicagoGarcia-Muñoz, R. (R.)|||/items/4cf158b6-e645-4ce5-8edc-8780b5f1a548, et al. Safety of Switching From Intravenous to Subcutaneous Rituximab During First-line Treatment of Patients With Non-Hodgkin Lymphoma: The Spanish Population of the MabRella Study. 2020.
Cita MLAGarcia-Muñoz, R. (R.)|||/items/4cf158b6-e645-4ce5-8edc-8780b5f1a548, et al. Safety of Switching From Intravenous to Subcutaneous Rituximab During First-line Treatment of Patients With Non-Hodgkin Lymphoma: The Spanish Population of the MabRella Study. 2020.